Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACTHAR gel Clear all
Completed Phase 4 Interventional

Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations

NCT01888354
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
H.P. Acthar Gel (repository corticotropin injection)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Oceanside, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 22, 2026, 8:06 AM EDT
Withdrawn Phase 4 Interventional

ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis

NCT01926054
View directory record Official record
Conditions
SLE Glomerulonephritis Syndrome, WHO Class V
Interventions
Acthar gel
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 22, 2026, 8:06 AM EDT
Withdrawn Phase 4 Interventional

Repository Corticotropin Injection in Keratoconjunctivitis Sicca

NCT03398018
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
repository corticotropin injection
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 22, 2026, 8:06 AM EDT
Not listed Phase 4 Interventional

Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)

NCT02188017
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Sarcoidosis
Interventions
Acthar gel
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 4 Interventional Results available

Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

NCT01753401
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Acthar, Placebo, Steroid Drug
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Jonesboro, Arkansas • La Jolla, California • La Palma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 22, 2026, 8:06 AM EDT
Terminated Phase 4 Interventional Results available

Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

NCT02057523
View directory record Official record
Conditions
Proteinuria, Transplant Glomerulopathy
Interventions
Acthar
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Not applicable Interventional Results available

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

NCT02725177
View directory record Official record
Conditions
Ocular Sarcoidosis, Panuveitis, Anterior Uveitis
Interventions
Repository Corticotropin Injection, Repository Corticotropin Injection -Treatment Extension
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

NCT01601236
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Repository Corticotropin Injection, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
10
States / cities
Roseville, California • Cooper City, Florida • Miami Springs, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 3 Interventional Results available

ACTH for Fatigue in Multiple Sclerosis Patients

NCT02315872
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
ACTH, Placebo
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Cullman, Alabama • Medford, Oregon • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 4 Interventional Results available

Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis

NCT02919761
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
San Leandro, California • Upland, California • Boynton Beach, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 4 Interventional

Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus

NCT01769937
View directory record Official record
Conditions
Lupus Erythematosus Systemic Exacerbation
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Fiechtner, Justus J., M.D., P.C.
Individual
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Oct 22, 2026, 8:06 AM EDT
Suspended No phase listed Observational

Safety and Efficacy of Combination Acthar Gel and Tacrolimus in the Treatment of Steroid Resistant Nephrotic Syndrome

NCT03042637
View directory record Official record
Conditions
Nephrotic Syndrome
Interventions
Acthar Gel and Tacrolimus
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 4 Interventional Results available

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

NCT02633046
View directory record Official record
Conditions
Idiopathic Focal Segmental Glomerulosclerosis
Interventions
Acthar Gel
Drug
Lead sponsor
Mallinckrodt ARD LLC
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
21
States / cities
Birmingham, Alabama • Tucson, Arizona • Chula Vista, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 22, 2026, 8:06 AM EDT
Not listed No phase listed Observational

Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function

NCT03644771
View directory record Official record
Conditions
Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function
Interventions
Acthar
Drug
Lead sponsor
Greater Boston Medical Associates
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 3 Interventional Results available

Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT02282930
View directory record Official record
Conditions
Progressive IgA Nephropathy, Proteinuria
Interventions
ACTH (Acthar) Gel
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Palo Alto, California • Jacksonville, Florida • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 22, 2026, 8:06 AM EDT
Withdrawn Phase 4 Interventional

Acthar on Proteinuria in IgA Nephropathy Patients

NCT02382523
View directory record Official record
Conditions
IgA Nephropathy, Proteinuria
Interventions
Acthar 80 unit injection
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 22, 2026, 8:06 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population

NCT02486744
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Acthar Gel
Drug
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Canfield, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 4 Interventional Results available

Adrenocorticotropic Hormone in Membranous Nephropathy

NCT03025828
View directory record Official record
Conditions
Membranous Nephropathy
Interventions
ACTHar
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 22, 2026, 8:06 AM EDT
Terminated Phase 4 Interventional Results available

Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar

NCT02546492
View directory record Official record
Conditions
Transplant Glomerulopathy
Interventions
Acthar gel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 4 Interventional Results available

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

NCT02764697
View directory record Official record
Conditions
Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Scleritis, Clinically Significant Macular Edema
Interventions
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
Drug
Lead sponsor
Tampa Bay Uveitis Center, LLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 22, 2026, 8:06 AM EDT
Completed No phase listed Observational

Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse

NCT02633033
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Not listed
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
38
States / cities
Homewood, Alabama • Tucson, Arizona • Colorado Springs, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 22, 2026, 8:06 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis

NCT02434757
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Ronald J. Rapoport, MD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fall River, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis

NCT02245841
View directory record Official record
Conditions
Dermatomyositis, Juvenile Dermatomyositis
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 4 Interventional Results available

Acthar Gel in Participants With Pulmonary Sarcoidosis

NCT03320070
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 22, 2026, 8:06 AM EDT